ArticleFrontiers in oncology2026
Collagenous endobronchial obliteration after chemoradiation followed by consolidation osimertinib: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Consolidation osimertinib after concurrent chemoradiation is a standard treatment for unresectable stage III Case presentation: We report an 83-year-old woman who developed acute dyspnea and complete right-lung atelectasis 3 months after completion of concurrent chemoradiation therapy while receiving consolidation osimertinib. Bronchoscopy showed membranous occlusion of all three right lobar bronchi, and biopsy demonstrated dense collagenous tissue admixed with fibrin and mild inflammation. Systemic glucocorticoid therapy and temporary interruption of osimertinib led to initial clinical improvement, but the obliteration recurred during corticosteroid tapering. Discussion: Compared with previously reported cases, our case demonstrated a more advanced fibrotic process, together with extensive involvement of all three right lobar bronchi within the irradiated field. Notably, this fibrotic change developed earlier than is typical for radiation-induced fibrosis. While radiation-induced airway injury was the principal cause, the early onset raises the possibility that osimertinib also contributed by impairing epithelial repair through EGFR inhibition. Conclusions: Clinicians should be aware of the potential for collagenous endobronchial obliteration, particularly in patients with centrally located tumors receiving chemoradiation followed by consolidation osimertinib. Bronchoscopic evaluation may facilitate diagnosis, whereas systemic glucocorticoid therapy with gradual tapering and close monitoring may aid management in similar cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.